Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26

Gastrin‐releasing peptide receptors (GRPRs) are overexpressed in prostate cancer and are suitable for targeted radionuclide therapy (TRT). We optimized the bombesin‐derived GRPR‐antagonist PEG(2)‐RM26 for labeling with (177)Lu and further determined the effect of treatment with (177)Lu‐labeled pepti...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Int J Cancer
Glavni autori: Mitran, Bogdan, Rinne, Sara S., Konijnenberg, Mark W., Maina, Theodosia, Nock, Berthold A., Altai, Mohamed, Vorobyeva, Anzhelika, Larhed, Mats, Tolmachev, Vladimir, de Jong, Marion, Rosenström, Ulrika, Orlova, Anna
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2019
Teme:
Cancer Therapy and Prevention
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6852655/
https://ncbi.nlm.nih.gov/pubmed/31077356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32401
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items